Predictors of anti-vascular endothelial growth factor treatment responses in macular edema following central vein occlusion.
- Author:
Peirong HUANG
1
;
Zhengyu SONG
2
;
Xiaodong SUN
3
Author Information
1. Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai 200080, China.
2. Shanghai Key Laboratory of Fundus Disease, Eye Research Institute of Shanghai Jiao Tong University, Shanghai 200080, China.
3. Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai 200080, China. Email: xdsun@sjtu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal, Humanized;
therapeutic use;
Aptamers, Nucleotide;
therapeutic use;
Bevacizumab;
Humans;
Macular Edema;
drug therapy;
Ranibizumab;
Receptors, Vascular Endothelial Growth Factor;
therapeutic use;
Recombinant Fusion Proteins;
therapeutic use;
Retinal Vein Occlusion;
drug therapy;
Vascular Endothelial Growth Factor A;
antagonists & inhibitors;
Visual Acuity;
drug effects
- From:
Chinese Medical Journal
2014;127(16):3019-3023
- CountryChina
- Language:English
